BGPT: Author Review: Ying Xu

Explore by Goal

Quick Explanation Copied

Author scope is ambiguous (name disambiguation)

The provided raw “Author Review: Ying Xu” content does not uniquely identify which “Ying Xu” (among multiple OpenAlex matches) authored the listed papers; many entries appear to correspond to a different co-occurring author name (“Yingxu Chen”). Because of that, the scientific-strength assessment below is limited to the papers and excerpts explicitly included in your data dump.

Long Explanation

BGPT Skeptical Science Review — “Author Review: Ying Xu”

Epistemic humility note: the dataset you provided mixes multiple “Ying Xu”/“Yingxu …” identities; I therefore grade scientific strength based only on the included paper-level methods/results excerpts, not on a verified publication record for a single individual.

1) What the included papers suggest about scientific strengths

Mechanistic causal dissection using targeted perturbations

Circadian-cell biology: PER2–CK1δ docking was disrupted by defined mutations (e.g., V729G/L730G in PER2 context), with downstream effects on PER phosphorylation/stability, CLOCK phosphorylation, and CLOCK–BMAL1 DNA association tested with biochemical assays and in vivo mouse genetics. Evidence includes reciprocal impacts of docking-site mutations on phosphorylation and degradation kinetics, plus RNA-seq/ChIP readouts, with deposited sequencing data. Ref:
Virology/host restriction: SAMHD1 expression and susceptibility to Vpx-mediated degradation were probed across primary human cell types (CD4+ T cells vs monocytes), with immune activation state explicitly tested using immune stimuli and IFN-α modulation, plus SIV-Vpx degradation assays and flow cytometry. Ref:
Epigenetics/chromatin logic: acute CTCF depletion (auxin-induced degradation) was paired with genome-wide ATAC-seq, WGBS (methylation), Hi-C, RNA-seq/proteomics/phosphoproteomics, and a TF dropout screen to identify co-regulatory partners. Ref:

Cross-level translational framing (molecules → cells → systems)

Skin immunology/autoimmunity: keratinocyte SPRY1 deletion in mice was linked to DGAT2 protein/lipid changes, with claims extending to human psoriatic datasets and CD8+ T-cell activation consequences, combining lipidomics, bulk & scRNA-seq, functional assays, and GEO depositions. Ref:
Microbe–host metabolite endocrinology: nasal S. aureus carriage was linked to depressive phenotypes in humans (observational association) and mice (microbiota transplantation/colonization plus causal hormone degradation via an identified enzyme class). Mechanistic enzyme evidence used in vitro degradation and gene deletion. Ref:

2) Visual evidence maps (from your provided raw excerpts)

These visuals do not assign numeric scores beyond what is explicitly stated in your dataset; they structure the included studies by evidence type and typical validation depth.

3) Critical appraisal: limitations & blind spots visible from the excerpts

Common limitation patterns

Generalizability: several excerpted studies rely on model organisms or specific cell lines; even when mechanisms are strong, translation can be limited by species and tissue context differences. Example: the MAVS localization/metabolic axis uses mouse and multiple cell lines and does not claim genome-wide human generality.
Data-cycle constraints: in the circadian study, RNA-seq is limited to one circadian cycle, which can miss rhythms that appear at other phases/cycles.
Human evidence type: microbiome/nutrition/cancer biomarker review and some observational elements are prone to confounding; narrative reviews add synthesis but are not primary mechanistic evidence. Example: the immune/cancer microbiome review is explicitly narrative and highlights heterogeneity and limited randomized evidence.
Sample size constraints: several human-cohort or long-follow-up studies in your dataset have modest long-term n or single-center design issues (important for effect size overestimation risk). Example: the long-term BCI-FES stroke study excerpt notes small long-term follow-up sample and potential selection bias.
Reproducibility & availability: while many mechanistic papers include deposited datasets, some review or model-therapy/device-excerpts do not provide sufficient independent replication detail in the excerpt. Example: inflammatory biomarker modeling in gastric cancer uses retrospective multi-center data but external validation is recommended and may be lacking.

4) Evidence-strength “what would change my mind” checklist

These items are derived from the provided “how_to_falsify” fields and limitations embedded in the excerpts, not from any external inference.

5) Bottom-line grade (based on the included excerpts only)

Scientific strength is most visible when the excerpt shows (i) precise perturbations, (ii) mechanistic readouts, and (iii) multi-modal validation with traceable data deposits.
Scientific weakness risk is most visible when the excerpt is observational, narrative, retrospective/model-based, or uses limited sample size/time windows (all of which can inflate effect sizes or miss context dependence).
Most important uncertainty: whether all cited excerpts correspond to the same “Ying Xu” individual (the provided material contains name-disambiguation ambiguity). This uncertainty limits confidence in author-level attribution rather than in the science of each individual paper.

Disambiguation warning (required)

Your dataset includes OpenAlex-like matches where multiple “Ying Xu” variants exist, but the paper excerpts shown include DOIs for studies that likely involve a different author name variant. If you provide the exact DOI list or an ORCID for “Ying Xu,” I can re-grade attribution confidence.

Feedback:

Updated: April 01, 2026